Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr1404 Inhibitors

Olr1404 inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of the Olr1404 receptor, an olfactory receptor that is part of the G protein-coupled receptor (GPCR) superfamily. These receptors are essential in the olfactory system, where they are responsible for detecting odorant molecules and translating these chemical signals into neural responses that the brain interprets as distinct smells. Olr1404 inhibitors function by binding to the receptor's active site, where natural odorants would typically bind, or by interacting with allosteric sites that can modulate the receptor's activity. This binding effectively prevents the receptor from undergoing the conformational changes necessary for activating downstream intracellular signaling pathways. By inhibiting these processes, Olr1404 inhibitors block the receptor's ability to transmit olfactory signals, thereby disrupting the normal function of the olfactory system in sensing and identifying smells. The design and development of Olr1404 inhibitors often involve detailed structural studies of the receptor, utilizing advanced techniques such as X-ray crystallography, molecular modeling, and cryo-electron microscopy. These structural insights are crucial for designing inhibitors that are highly specific to the Olr1404 receptor and effective in modulating its activity without affecting other similar receptors.

Chemically, Olr1404 inhibitors exhibit a wide range of molecular structures, reflecting the various synthetic strategies used in their development. These compounds can vary from small, lipophilic molecules capable of easily crossing cellular membranes to reach their target receptors, to larger, more complex structures that may require sophisticated synthetic techniques to achieve optimal binding affinity and specificity. The synthesis of Olr1404 inhibitors typically involves multiple steps of organic chemistry, including the construction of molecular frameworks and the incorporation of functional groups that enhance the compound's interaction with the receptor. Once synthesized, these inhibitors undergo rigorous characterization using a variety of analytical techniques, such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, and high-performance liquid chromatography (HPLC). These methods are employed to confirm the structural integrity, purity, and inhibitory potency of the compounds. The study of Olr1404 inhibitors is important for advancing our understanding of the specific mechanisms by which this olfactory receptor operates and how its activity can be modulated by small molecules. Additionally, this research contributes to the broader field of GPCR biology, offering valuable insights into the molecular processes underlying sensory perception, particularly in the context of olfaction. By deepening our knowledge of how olfactory receptors function and how they can be selectively targeted, scientists can explore new avenues in the study of sensory systems and the complex biochemical pathways that govern them.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

EGFR inhibitor, might disrupt cell signaling in non-small cell lung cancer by blocking EGFR tyrosine kinase.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Targets multiple tyrosine kinases, could inhibit cell proliferation and angiogenesis in renal cell carcinoma.

XL-184 free base

849217-68-1sc-364657
sc-364657A
5 mg
10 mg
$94.00
$208.00
1
(1)

Targets MET, VEGFR, and AXL, might affect cell survival and angiogenesis in medullary thyroid cancer.

Cobimetinib

934660-93-2sc-507421
5 mg
$270.00
(0)

MEK inhibitor, could disrupt the MAPK/ERK pathway, affecting cell proliferation in melanoma.

Dabrafenib

1195765-45-7sc-364477
sc-364477A
sc-364477B
sc-364477C
sc-364477D
5 mg
25 mg
50 mg
100 mg
10 g
$141.00
$260.00
$278.00
$411.00
$12485.00
6
(1)

Targets BRAF V600E mutation, potentially inhibiting the MAPK pathway in melanoma.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Src and ABL kinase inhibitor, might inhibit cell growth and survival in chronic myeloid leukemia.

CAL-101

870281-82-6sc-364453
10 mg
$193.00
4
(1)

PI3K delta inhibitor, could impact signaling in B-cell malignancies.

Lenvatinib

417716-92-8sc-488530
sc-488530A
sc-488530B
5 mg
25 mg
100 mg
$182.00
$661.00
$1690.00
3
(0)

Targets VEGF receptors, FGFR, RET, KIT, potentially affecting cell proliferation in thyroid cancer.

Neratinib

698387-09-6sc-364549
sc-364549A
sc-364549B
sc-364549C
sc-364549D
5 mg
25 mg
100 mg
500 mg
1 g
$92.00
$214.00
$383.00
$755.00
$1250.00
4
(1)

Irreversible inhibitor of HER2 and EGFR, might inhibit cell proliferation in breast cancer.

Pazopanib

444731-52-6sc-396318
sc-396318A
25 mg
50 mg
$130.00
$182.00
2
(1)

Inhibits VEGF receptors, PDGFR, and KIT, could impact angiogenesis in renal cell carcinoma.